Incretin Atlas › Trials › GRADUAL-1 (NCT06728124)
GRADUAL-1 (NCT06728124)
Bofanglutide (GZR18) · obesity
Design
- Molecule(s)
- Bofanglutide (GZR18)
- Population
- obesity
- Official title
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects
- Sponsor
- Gan & Lee Pharmaceuticals.
- Phase
- 3
- Registry status
- completed · 2024-12 → 2026-03
- Participants
- 640
- Duration
- 52 weeks
- Registry
- NCT06728124
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24 mg Q2W | obesity china | 52 | 640 | — | —−15.1 % vs −1.1 % estimand not specified | — | — | — | — | — | — | — | press release |
| 48 mg Q2W | obesity china | 52 | 640 | — | —−18.5 % vs −1.1 % estimand not specified | — | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (2)
- 24 mg Q2W · weight_unsp · press release
achieved mean body weight reductions of 15.12% and 18.54%, respectively, compared with 1.11% in the placebo group
- 48 mg Q2W · weight_unsp · press release
achieved mean body weight reductions of 15.12% and 18.54%, respectively, compared with 1.11% in the placebo group
Primary sources
- Gan & Lee. Gan & Lee: Insulin Ludefen meets Phase III endpoint; Bofanglutide meets primary endpoints in Phase III weight-loss study in China (GRADUAL-1) and Phase II in the U.S. (Macau Business mirror of PR Newswire) [press release]. 2026-06-12. Available from: https://macaubusiness.com/gan-lee-pharmaceuticals-achieves-significant-progress-in-its-dual-pipeline-for-metabolic-diseases-weekly-insulin-ludefen-gzr4-meets-primary-endpoint-in-phase-iii-clinical-trial-in-china-bo/
- ClinicalTrials.gov NCT06728124
How to cite this page
Medical Adviser's Group. Incretin Atlas: GRADUAL-1 (NCT06728124). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/gradual-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.